CD274 and cancer: PD‐1 and its ligand play an important role in the antitumor immune response by inhibiting T‐cell activation, cytokine production, and cytolytic function, while anti‐PD‐1/PD‐L1 monoclonal antibodies (mAbs) inhibit the interaction between the inhibitory receptor on T cells and its ligands on cancer cells, thereby reestablishing T‐cell reactivity and antitumor effector functions [2].